What is it about?
We examined biomarkers to predict the therapeutic effectiveness of benralizumab, an anti-interleukin (IL)-5 receptor antibody, in patients with severe asthma. This study offers evidence supporting circulating miRNAs as biomarkers for assessing benralizumab's effectiveness in patients with severe asthma.
Featured Image
Photo by Vitaly Gariev on Unsplash
Why is it important?
These findings promote the development of precision medicine approaches for asthma management.
Perspectives
The potential to easily measure these miRNAs in clinical settings could enhance treatment decisions and lead to better outcomes.
Keita Hirai
Shinshu Daigaku
Read the Original
This page is a summary of: Identification of potential transcriptomic and microRNA markers to assess benralizumab effectiveness, Journal of Allergy and Clinical Immunology, July 2025, Elsevier,
DOI: 10.1016/j.jaci.2025.06.025.
You can read the full text:
Resources
Contributors
The following have contributed to this page
